new advances and opportunities for improvement in hr /her2- early breast cancer
Published 2 years ago • 3.7K plays • Length 29:21Download video MP4
Download video MP3
Similar videos
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
55:30
breaking down barriers to treatment adherence and persistence in hr /her2- early breast cancer
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
1:16:56
navigating the integration of trop2-targeted therapy in tnbc and hr , her2- breast cancer
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
1:01:32
the role of ai in hr: opportunities and challenges
-
1:40:47
clarifyingcomplexities of expandingtreatmentoptionsfor advancedandearly-stage hr /her2- breastcancer
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
48:13
empowering changes and revolutionizing treatment and equity in breast cancer
-
1:35:31
leveraging targeted therapies to improve outcomes across the continuum of her2 breast cancer
-
1:14:57
embracing progress, transforming treatment, empowering patients
-
1:33:57
evaluating the evidence and parsing the practicalities of therapeutic choices in hr breast cancer
-
32:54
raising the bar in her2-positive breast cancer
-
57:18
translating progress with immunotherapies and targeted agents into improved outcomes in tnbc
-
4:45
advances and considerations in the treatment and management of hr , her2-, advanced breast cancer
-
59:12
making precision decisions in high-risk hr , her2- metastatic breast cancer
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer